Neovacs Announces Completion of Safety Data Review
An independent Data and Safety Monitoring Board has completed the successful review of the safety data of the Phase IIb clinical trial of TNF-Kinoid in rheumatoid arthritis
An independent Data and Safety Monitoring Board has completed the successful review of the safety data of the Phase IIb clinical trial of TNF-Kinoid in rheumatoid arthritis (RA), according to an annual statement issued by Neovacs.
The biotech company, which focuses on an active immunotherapy technology platform with applications in autoimmune and/or inflammatory diseases, has now received a final report in with unrestricted approval of the study. The committee of four international auto-immune disease experts have confirmed the good safety profile of the Kinoid at the actual stage of the study, and made a unanimous recommendation to pursue the study without modification, stated Neovacs.
"From a clinical point of view, 2013 was an important year for Neovacs, with the launch of our phase IIb trial in RA. 2014 will also be a critical year. The RA clinical study is progressing according to schedule,” said Miguel Sieler, CEO of Neovacs. “We are also resuming preclinical studies with three other Kinoids, in order to maintain our leadership position in the development of immunotherapies for the treatment of auto-immune diseases, chronic infections and cancer. I am confident that the clinical data that we will present in 2014 will prove the efficacy of our products, and allow Neovacs to reach the next phase of its development".
Read the full release here.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
